Refer to local Trust guidance for advice on the prescribing and monitoring of low molecular weight heparins.
Due to the differences in injectable device, all enoxaparin prescribing should be by brand name. In addition, due to the availability of biosimilar versions of enoxaparin, MHRA guidance to prescribe by brand name should be followed.
Switching between brands should be as a last resort after full training in the use of the new device has taken place.
Care when prescribing/selecting strength of syringes - Different strengths available.
|